Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620373 · ClinicalTrials.gov registry record · NA
Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 969
- Enrollment target
NCT00620373: Completed NA study, sponsored by Mayo Clinic.
NCT00620373 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 969 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620373, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 969 participants
- Enrollment target
Study Summary
We aim to compare the sensitivity of mammography to the sensitivity of Molecular Breast Imaging (a new gamma-camera based breast imaging technology) in women with dense breast tissue who are at increased risk for breast cancer.
Primary Outcome
Diagnostic yield is the likelihood that a test or procedure will provide the information needed to establish a diagnosis. In this case, it is the proportion of women with positive results of a screening test and positive results with the reference standard (verified cancer status).
Interventions
- DEVICE Molecular Breast Imaging
- DEVICE Conventional Mammography
- DRUG Technetium (99mTc) sestamibi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 969 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-06 |
| Phase | NA |
What the finished NCT00620373 record still lists
NCT00620373 is an interventional study that assigns participants to a tested intervention. The registered 969 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 3 interventions - of which Molecular Breast Imaging is the first listed.
NCT00620373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00620373 about?
NCT00620373 is a clinical study titled "Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts". We aim to compare the sensitivity of mammography to the sensitivity of Molecular Breast Imaging (a new gamma-camera based breast imaging technology) in women with dense breast tissue who are at increased risk for breast cancer.
What is the current status of trial NCT00620373?
This trial is currently completed. It is a NA study. The enrollment target is 969 participants. The study started on 2005-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00620373?
The interventions under investigation include: Molecular Breast Imaging (DEVICE), Conventional Mammography (DEVICE), Technetium (99mTc) sestamibi (DRUG).
Who is sponsoring clinical trial NCT00620373?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00620373's enrollment target sits among peer trials
969 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia